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Abstract ] 
Because GHB (y-hydroxybutyrate) is present in both blood and 
urine of the general population, toxicologists must be able to 
discriminate between endogenous levels and a concentration 
resulting from exposure. In this paper, we propose a procedure for 
the detection of exogenous GHB in blood by gas 
chromatography-combustion-isotope ratio mass spectrometry 
(GC-C-IRMS). Following liquid-liquid and solid-phase extractions, 
GHB is derivatized to GHB di-TMS before analysis by GC-C-IRMS. 
Significant differences in the carbon isotopic ratio (A613C-values 
> 13.5%o) were found between endogenous and synthetic GHB. 
Indeed, for postmortem blood samples with different GHB 
concentrations (range: 13.8-86.3 rag/L), we have obtained GHB 
813C-values ranging from -20.6 to -24.7%o, whereas ~13C.values 
for the GHB from police seizure were in the range -38.2 to 
-50.2%0. In contrast to the use of cut-off concentrations for 
positive postmortem blood GHB concentrations, this method 
should provide an unambiguous indication of the drug origin. 
Introduction 
y-Hydroxybutyrate (GHB) is a substance naturally present 
within mammalian species. Neurotransmitter or neuromodu- 
lator properties are generally associated with th s substance (1). 
GHB has been used medically for induction of anesthesia (2), 
treatment of narcolepsy (3), and treatment of alcohol and opiate 
withdrawal (4,5). Besides its therapeutic effects, this drug has 
become popular with people such as body builders for stimu- 
lating the release of growth ormone (6) and ravers or club at- 
tendees for its intoxicating effects such as euphoria, reduced 
inhibitions, sedation, and muscle relaxation (7). Moreover, th  
purported enhancement of sexuality, coupled with a possible 
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abrupt coma-inducing effect, ease of administration in spiked 
drinks, and potential amnesia hasresulted in the use of GHB as 
an assault-related drug. GHB is also attractive to rapists as it is 
readily available onthe Internet, on the street, and in dance 
clubs or fitness centers. 
In both clinical and forensic investigations, determining 
whether any GHB detected is due to endogenous production or
exogenous ingestion is usually required. There have been in- 
creasing data suggesting that antemortem endogenous GHB 
concentrations are less than 10 and 5 mg/L in urine and blood, 
respectively (8,9). The presence of GHB in postmortem fluid has 
also been evaluated, although the available data have be n sub- 
ject to controversy (10,11). Very recently, interpretative cut-offs 
based on GHB concentrations measured incases unrelated to 
GHB ingestion have been proposed for bothpostmortem blood 
and urine (12). Indeed, it has been estimated hat at blood con- 
centrations less than 30 mg/L and at urine concentrations le s 
than 20 mg/L, it may be possible that any GHB detected isen- 
dogenous. However, ithas also been shown that a positive post- 
mortem blood GHB concentration cannot support drug 
exposure alone and that it is essential to document the case 
with other specimens, including peripheral blood and vitreous 
humor (13). 
To have an alternative to the use of GHB interpretative con- 
centration cut-offs, we propose here amethod using contin- 
uous-flow gas chromatography-combustion-isotopic ratio 
mass spectrometry (GC-C-IRMS) technique to discriminate 
between endogenous and exogenous GHB in blood. Carbon 
isotope ratios (13C/12C) of synthetic GHB is expected todepend 
on both the origin of the precursors and on the synthetic route 
used, whereas the carbon isotopic composition of endogenous 
GHB will depend strongly on the food diet and will be influ- 
enced by additional effects of human biological processing. I  
this study, we report he carbon isotope ratios of GHB in post- 
mortem blood samples with endogenous GHB production and 
in a blood sample from a subject exposed to GHB. The carbon 
isotope ratios f GHB in these blood samples are also corn- 
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pared with those of GHB samples from police seizures and 
manufacturers. To date, there is no report of application of the 




Methanol (CH3OH), dimethyformamide (DMF), hexane, am- 
monium hydroxide (NH4OH), and potassium hydroxide of an- 
alytical grade purity were obtained from Fluka (Buchs, 
Switzerland). NaH2PO4 of analytical grade purity was from 
Merck (Darmstadt, Germany). The 0.1M phosphate buffer (pH 
6.0 • 0.1) was prepared from 0.1M NaH2PO 4and 5M sodium hy- 
droxide. GHB standards (1 mg/mL in methanol) were pur- 
chased from Cerilliant (Austin, TX), Lipomed (Arlesheim, 
Switzerland) and Cambridge Isotope Laboratories (CIL) 
(Andover, MA). 7-Butyrolactone (GBL) with a purity > 99% was 
obtained from Aldrich (Steinheim, Germany). Bis(trimethyl- 
silyl)-trifluoroacetamide (BSTFA) with 1% trimethylchlorosi- 
lane (TMCS) was purchased from Supelco (Bellefonte, PA). 
Deionized water was prepared using a Millipore purification 
system. The extraction columns were CLEAN SCREEN | 
CSGHB203 from United Chemical Technologies, Inc. (Bristol, 
PA). The reference carbon dioxide gas was purchased from 
Carbagaz (Domdidier, Switzerland). The mixture of three 
alkanes, C15 (n-pentadecane), C20(n-eicosane), and C25 (n-pen- 
tacosane) with 613C-values of-30.22,-33.06, and -28.21%o, 
respectively, was supplied by Chiron AS (Trondheim, Norway). 
GHB seizure samples and blood specimens 
GHB seizure samples in powder form were obtained from dif- 
ferent police d partments in France. Blood specimens withthe 
presence of endogenous GHB (from 13.8 to 86.3 IJg/mL) were 
obtained from the autopsy room. For all these postmortem 
blood specimens collected in the autopsy room, there was no 
suspicion of GHB consumption before death. The blood sample 
of a subject exposed to GHB (215 mg/L) was collected at the 
emergency unit of the local hospital. A positive control with a 
GHB concentration f 50 t~g/mL was obtained from the blood 
of a healthy subject spiked with a GHB standard (1 mg/mL in 
methanol) purchased from Cerilliant. Each blood sample was 
preserved inEDTA tubes and stored at +4~ until GC-MS mea- 
surements. Afterwards, the tubes were stored at -20~ until 
GC-C-IRMS analysis. 
Sample preparation 
The concentration f GHB is determined previously by a 
rapid standard procedure (14). Knowing the concentration f 
GHB, a minimum blood volume corresponding to 4 mg GHB is 
treated with 1 mL acetone in a 15-mL glass tube. After a me- 
chanical agitation for 5 min and centrifugation at2500 rpm for 
5 min, the supernatant is collected and evaporated o ryness 
at 50~ under a nitrogen stream (Turbo Vap LV evaporator, Zy- 
mark, Hopkinton, MA). Subsequently, the residue is redissolved 
in I mL of 0.1M phosphate buffer (pH 6.0 • 0.1), and the mix- 
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ture is vortex mixed for about 10 s. Then, the solution is applied 
onto a CLEAN SCREEN GHB extraction column, which is pre- 
viously conditioned with successive addition of 3 mL methanol, 
3 mL deionized water, and 1.0 mL 0.1M phosphate buffer (pH 
6.0 • 0.1). The sample is loaded onto the extraction column, 
and the aspirate iscollected in a 10-mL glass tube. The original 
sample tube is washed with I mL of CH3OH/NH4OH (99:1), and 
the wash solution is decanted into the column. The column is 
aspirated into the 15-mL glass tube that contained the first 
aspirate. The resulting solution is evaporated to dryness at 
50~ under a nitrogen stream. Dimethylformamide (400 IJL) is 
added to the tube containing the residue followed by I mL of 
hexane saturated with dimethylformamide. Then, the tube is 
mixed by inversion for 5 min and centrifuged at 2500 rpm for 
5 min. The top hexane layer is discarded, and the lower DMF 
layer is transferred to aclean 15-mL glass tube. The DMF layer 
is evaporated to dryness at 50~ under a nitrogen stream and 
derivatized with 50 IJL of BSTFA + 1% TMCS. The extract is 
vortex mixed and heated for 5 rain at 60~ Finally, the solution 
is transferred to an auto-sampler vial for GC-MS and contin- 
uous flow GC-C-IRMS analysis. 
GC-MS analysis 
The GC-MS analysis was performed on a Hewlett-Packard 
5890 series II Plus chromatograph (HP Analytical Division, 
Waldbronn, Germany) equipped with an HP 7673 autosampler 
and coupled with an HP 5971 mass selective detector. GC sep- 
aration was achieved on an HP cross-linked 50% phenyl- 
methylsiloxane fused silica capillary co umn (30 m x 0.25-ram 
i.d., 0.15-lJm film thickness) from J&W Scientific (Folsom, 
CA). For the analysis of GHB di-trimethylsilyl (TMS), the oven 
temperature was increased from 70~ (1 rain) to 100~ at 
10~ then to 295~ at 30~ and maintained atthe 
final temperature for 1 rain. Injections of 1-1JL samples were 
made at 280~ in the splitless mode. Et mass spectra were 
recorded by continuous scanning in the mass range 50-450 at
an ionization potential of 70 eV. 
GC-C-IRMS analysis 
The carbon isotope measurements were performed on a 
Delta Plus IRMS system (Thermo Finnigan MAT, Bremen, Ger- 
many) coupled to an Agilent 6890A GC (HP Analytical Division, 
Waldbronn, Germany) via a Finnigan GC Combustion III in- 
terface (Thermo Finnigan MAT) and a CTC Analytics CombiPal 
autosampler (CTC Analytics AG, Zwingen, Switzerland). Chro- 
matographic separations were achieved on a HP cross-linked 
50% phenylmethylsiloxane fused silicacapillary column (30 
m x 0.25-mm i.d., 0.15-]Jm film thickness) from J&W Scientific 
(Folsom, CA). The injector temperature was set to 280~ The 
combustion and reduction oven temperatures were set to 940~ 
and 600~ respectively. Reference carbon dioxide gas pulses (20 
s durations) were introduced at different imes during the 
course of the chromatographic separation. For the calibration 
of the reference gas with the alkane mixture of known 613C - 
values, the oven temperature was increased from 80~ (1 rain) 
to 270~ (7.0 rain) at 15~ For the analysis of GHB di- 
TMS, the oven temperature was increased from 70~ (1 rain) to 
100~ at 10~ then to 295~ at 30~ and main- 
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tained at the final temperature for 1 min. The volume of injec- 
tion was 2 IJL, and the extracts were injected in the splitless 
mode. 
The symbol a is the standard notation for expressing carbon 
isotope ratios. It is defined as parts per thousand eviation of 
isotopic compositions from that of Pee Dee Belemnite and is 
calculated according to 
(~13C/%o = (13C/12C)sample - (13C/12C)standard X 1000 Eq. 1 
(13C/12C)standard 
If there is no isotopic fractionation during the GHB silylation 
reaction, then the ~13C-value of the derivatized GHB di-TMS is 
the carbon-weighted average of th  isotope signatures ofGHB 
and TMS: 
a13CGHB di-TMS = ~ al3CGHB + ~ t~13CoTMS Eq. 2 
According to a published procedure (15), the 513C-value ofthe 
added silyl carbon atoms (~paCoTM s) was -47.9 + 0.30%0 for 
the reagent batch used throughout the study. Therefore, the 
[i13C-value of GHB can be calculated from the513C-value ofthe 
GHB di-TMS measured by GC-C-IRMS. 
Results and Discussion 
~13C values of GHB drug seizures and synthetic GHB 
A synthetic GHB standard from Cerilliant (1 mg/mL in 
methanol) was analyzed by GC-MS to determine the retention 
time and purity of the drug. The GC-MS analysis of GHB re- 
quired the formation of a TMS derivative to avoid peak tailing 
and loss of sample. This derivatization leads to the addition of 
six carbon atoms to a molecule possessing four carbon atoms 
(Figure 1). Therefore, using Eq. 2, the 813C-value ofGHB may 
be determined from the ii13C-value ofGHB di-TMS measured by 
continuous flow GC-C-IRMS. In contrast to GHB, the TMS 
derivative ofGHB (minjected = 400 ng) was found to give a stable 
signal by GC-C-IRMS and very reproducible carbon isotopic 
values (Table I). Moreover, the IRMS response for GHB di-TMS 
was linear from 60 to 900 ng. GC-C-IRMS analyses of four 
GHB standards at a concentration f 1 mg/mL gave ~p3C-value 
of GIIB di-TMS ranging from -44.0 to -48.3%0 (Table I). After 
correction of the carbon isotopic ratio according to Eq. 1, we 
calculate GHB 513C-value ranging from -38.2 to -48.2%0. Sim- 
ilarly, the carbon isotopic values of five GHB samples (solid 
form) from drug seizures dissolved in methanol at a concen- 
tration of I mg/mL are ranging from -38.2 to-50.2%o (Table I). 
It is noteworthy that the uncertainty for the GHB 813C-value 
is relatively high because the derivatization process adds more
O CH3 O 
OH J V V "O__S i - -CH 3 
C:H3 ~H3 
GHB GHB di-TMS 
Figure 1. Chemical structures of/-hydroxybutyrate and T-hydroxybutyrate 
di-TMS. 
carbons than that ofthe molecule to be analyzed. According to 
a procedure given in the literature (16), we would obtain a 
theoretical uncertainty of1.09%o n the GHB i513C-value with 
a standard eviation of 0.50%0 for TMS and GHB di-TMS 813C - 
values. Despite th  disadvantages caused by derivatization with 
two TMS groups, addition f six carbons to GHB will signifi- 
cantly increase the sensitivity of IRMS measurements. 
Isotope measurements of GHB in blood samples and 
accuracy of the method 
Routine procedures for the quantification of GHB in blood in- 
volve GC coupled to MS with two different approaches: GHB 
can be detected after cyclization to GBL in strong acid medium 
(17) or directly after liquid-liquid extraction (14,18). The 
liquid-liquid extraction of GHB resulted in no analyzable blood 
samples by GC-C-IRMS. Satisfying results were obtained by
coupling liquid-liquid extraction with a solid-phase method 
developed for isolation of GHB in urine and blood (19,20). 
Figure 2 shows a typical example of a GC-C-IRMS chro- 
Table I. 813C-Value of GHB di-TMS and GHB for Four 
Synthetic Standards and Five Seizure Samples (n = 3)* 
GHB di.TMS 
GHB 
813C-value/% o SD 813C-value/%~ 
Standard (Cerilliant) -44.02 0.09 -38.2 + 0.5 
Standard (CIL) -44.05 0.08 -38.3 + 0.5 
Standard (Lipomed) -48.27 0.10 -48.2 __. 0.5 
Standard * (Aldrich) -45.05 0.tl -40.8 + 0.5 
Seizure sample 1 -45.09 0.10 -40.9 + 0.5 
Seizure sample 2 -48.81 0.10 -50.2 _+ 0.5 
Seizure sample 3 -44.13 0.08 -38.5 -+ 0.5 
Seizure sample 4 -46.92 0.05 -45.5 _+ 0.5 
Seizure sample 5 -44.00 0.09 -38.2 _+ 0.5 
* Uncertainty in 613C-values of GHB has been calculated according to a procedure 
given in the literature (16). 
* Synthesized from y-butyrolactone (GBL) according to a published procedure (26). 
i ,u  
" 1000 
0 
400 4,50 500 550 
Time (s) 
Figure 2. GC-C-IRMS chromatogram (m/z 44) of derivatized GHB after 
extraction of a blood sample (100 pL) containing GHB at a concentra- 
tion of 50 mg/L. The square-topped peak represents a pulse of CO2 ref- 
erence gas. 
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matogram ofGHB extracted from blood. The chromatogram 
shows symmetrical peaks for the compounds of interest and no 
tailing. It should be noted that the poorly resolved signals be- 
tween 455 and 480 s were identified by GC-MS to be urea di- 
TMS and phosphoric acid tri-TMS. Finally, it is also noteworthy 
that he presence of GHB in the extracts was verified by GC-MS 
prior to any GC-C-IRMS analysis. 
Carbon isotopic measurements of GHB di-TMS are performed 
in the linear range of the instrument, and also include a posi- 
tive quality control. The purpose of the quality control is to 
verify the reproducibility ofthe extraction procedure andthe 
GC-C-IRMS measurements. The within-assay precision was 
determined by extracting six aliquots of the positive quality 
control and injecting each once within the same day. For the de- 
termination ofthe between-assay precision, x aliquots of the 
positive quality control were extracted over a period of two 
months, and injected once each. For the within-assay precision, 
we obtained a mean GHB di-TMS 813C-value of-43.68%o and 
SD = + 0.22%0 with the values ranging from--43.32 to -43.99%o. 
The statistics of the between-assay precision were --43.73%0 
and 0.43%0 for the mean GHB di-TMS 613C-value and SD, re- 
spectively, with a13C-values ranging from -42.99 to --44.12%o. 
These results indicate that the SD obtained for between-assay 
precision is slightly higher compared to the within-assay pre- 
cision. Moreover, the mean GHB di-TMS 813C-values of within- 
assay and between-assay precisions are similar to the GHB 
di-TMS 81gC-value of the standard from Cerilliant (Table I). 
These findings indicate a good reproducibility of the method 
and no significant isotopic fractionation duri g the extraction 
and analysis processes. 
Discrimination between endogenous and exogenous GHB 
To illicitly manufacture GHB, the industrial solvent GBL can 
be made alkaline with lye and heated; GHB powder is then pro- 
duced by adding acetone and by drying the mixture (21). GBL 
is produced in Japan based on the hydrogenation f maleic an- 
hydride, whereas in the United States and Europe, a major 
portion of GBL is currently being produced via the dehydro- 
genation of 1,4-butanediol, which is manufactured by the clas- 
sical Reppe process based on acetylene and formaldehyde (22). 
The isotopic signature of GHB will depend on the manufac- 
turing process and on the carbon feed stocks of the starting ma- 
terials. Based onthe GHB 813C-value offive seizure samples and 
Table II. ~13C-Values of GHB di-TMS and GHB for Five 
Postmortem Blood Samples and One Blood Sample of a 
Living Subject Exposed to GHB 
GHB GHB 
Concentration GHB di-TMS ~13C-Value 
Blood Samples (mg/t) [~13C-Value (%0) (%0) 
Living subject 215 -44.86 -40.3 
Postmortem 1 86.3 -36,96 -20.6 
Postmortem 2 26.6 -38.39 -24.1 
Postmortem 3 25.8 -37.52 -22.0 
Postmortem 4 22.5 -38.29 -23.9 
Postmortem 5 13.8 -38.62 -24.7 
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four standard (Table I), we may distinguish four isotopic signa- 
tures. If a manufacturing by the classical Reppe process is hy- 
pothesized, it is likely that the analyzed GHB samples have 
arisen from different carbon feed stocks with different isotopic 
signatures. It should be noted that GC-MS analyses of the 
seizure samples revealed no traces of GHB precursors (e.g., 
1,4-butanediol, maleic anhydride, GBL) and hence did not pro- 
vide information about he route of synthesis. 
Endogenous concentrations of living people may be influ- 
enced by factors uch as biochemical, drug-induced, and dietary 
effects (23). Endogenous production of GHB results in the brain 
from the metabolism of GABA with glutamic acid as a pre- 
cursor, whereas 1,4-butanediol, an endogenous product from 
fatty acids, may be a source of GHB in peripheral tissues (24). 
The most likely source of endogenous postmortem GHB pro- 
duction is putrescine (1,4-butanediamine), which will be sub- 
sequently converted to GABA by the action of several enzymes 
(21). Hence, it may be hypothesized thathe 13C and 12C content 
in the natural endogenous form of GHB will depend on the iso- 
topic carbon composition ofthe food diet and is influenced by 
additional effects of human biological processing. For the five 
postmortem blood samples with different GHB concentrations 
(range: 13.8-86.3 mg/L), we have obtained GHB di-TMS 813C - 
values ranging from -36.96 to -38.62%0 (Table II). After cor- 
rection of the carbon isotopic ratio following Eq. 1, we 
calculated GHB 813C-values ranging from -20.6 to -24.7%o. 
Although more data are needed to have a more descriptive 
statistic, these findings significantly show differences n the 
13C and 12C content of the natural endogenous with the syn- 
thetic form of GHB. The mean GHB di-TMS 8UC-value of the 
analyzed postmortem bloods is -37.96%o (n = 5, SD = 0.69%0 
and differs by more than 6%o from the synthetic GHB sample 
having the highest 13C content (Table I). A difference of 6.90%0 
is obtained between the mean GHB di-TMS 81:~C-value of the an- 
alyzed postmortem blood samples and the GHB di-TMS 81.~C - 
value of the living subject with a GHB concentration of 215 
mg/L. Although t e GHB concentration is far above the adopted 
cut-off for antemortem endogenous GHB concentrations i  
blood, the carbon isotopic measurement clearly reveals the 
synthetic origin of GHB. When a correction following Eq. 2 is 
applied, differences in the 813C-values between endogenous and 
exogenous GHB become more pronounced (A813C-values > 
13.5%o). 
Conclusions 
This method allows the discrimination between synthetic 
and endogenous GHB in blood samples with large variations of 
the carbon isotopic ratio. Nevertheless, further st dies a e still 
needed to adjust he positive identification threshold. For in- 
stance, it would be possible that the origin of GHB is both syn- 
thetic and endogenous in a blood sample with a total GHB 
concentration of 5 rng/L. To allow a discrimination in this case, 
a carbon isotopic study of GHB in a reference population of 
healthy subjects would be needed to determine a threshold 
value defined bythe mean 813C-value - 3SD. Then, the sample 
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could be declared positive with exogenous GHB if the carbon 
isotope value is lower than the threshold value. This proce- 
dure is applied in the detection of exogenous testosterone in 
urine by means of GC-C-IRMS (25). 
Although this method was successful for the analyses of post- 
mortem blood samples with GHB concentrations ranging from 
13.8 to 86.3 rag/L, further developments in the extraction pro- 
cess should be undertaken for postmortem blood samples with 
GHB concentrations lower than 10 mg/L. Indeed, this method 
requires the use of about 2.5 mL of blood for a sample with a 
GHB concentration f 2 mg/L. In addition, other developments 
should be made to analyze GHB in other matrices with the 
aim of determining if the carbon isotopic ratio f this sub- 
stance is maintained or if an isotopic discrimination occurs 
because ofthe mode of GHB production and absorption int  the 
body. 
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